Dr. Volker Sandig initiated ProBioGen’s cell line development program in 2000 resulting in the unique CHO.RiGHT® platform for protein production. He is co-inventor of key ProBioGen technologies including AGE1 designer cell lines, GlymaxX® and DirectedLuck®. His current work aims at modernizing manufacture of viral vectors and establishing new platforms for RNA delivery. This includes customized design of suspension cell lines for viral vaccines as well as packaging and producer cell lines for gene therapy vectors. For his innovation and contribution to the field of Animal Cell Culture Technology he received the Inaugural 2019 ESACT Innovation Award. Prior to joining ProBioGen, he led a research group at Merck Research Laboratories, USA, focusing on the development of manufacturing systems for gutless adenoviruses and vectored vaccines. Volker Sandig holds a medical degree and received his doctorate in Molecular Biology from the Humboldt University, Berlin, Germany.